Drug Profile
MBX 700
Alternative Names: MBX-700; SCH 900942Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Microbiotix
- Class Antivirals
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Hepatitis-C in USA
- 02 Jan 2013 Phase-I clinical trials in Hepatitis C in USA (unspecified)